MX2023003328A - Lineas de celulas de mamifero con desactivacion genica. - Google Patents

Lineas de celulas de mamifero con desactivacion genica.

Info

Publication number
MX2023003328A
MX2023003328A MX2023003328A MX2023003328A MX2023003328A MX 2023003328 A MX2023003328 A MX 2023003328A MX 2023003328 A MX2023003328 A MX 2023003328A MX 2023003328 A MX2023003328 A MX 2023003328A MX 2023003328 A MX2023003328 A MX 2023003328A
Authority
MX
Mexico
Prior art keywords
mammalian cell
cell lines
recombinant
gene knockout
cells
Prior art date
Application number
MX2023003328A
Other languages
English (en)
Inventor
Simon Auslaender
Benedikt Oswald
Niels Bauer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2023003328A publication Critical patent/MX2023003328A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En el presente documento se informa de un método para generar una célula de mamífero recombinante que expresa un polipéptido heterólogo y un método para producir un polipéptido heterólogo usando la célula de mamífero recombinante, en el que en la célula recombinante se ha reducido la expresión de al menos el gen endógeno MYC. Se ha descubierto que la desactivación de al menos el gen endógeno MYC en células de mamífero, por ejemplo, tales como células CHO, mejora la productividad recombinante por las células.
MX2023003328A 2020-09-24 2021-09-23 Lineas de celulas de mamifero con desactivacion genica. MX2023003328A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20197946 2020-09-24
PCT/EP2021/076165 WO2022063877A1 (en) 2020-09-24 2021-09-23 Mammalian cell lines with gene knockout

Publications (1)

Publication Number Publication Date
MX2023003328A true MX2023003328A (es) 2023-03-27

Family

ID=72644093

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003328A MX2023003328A (es) 2020-09-24 2021-09-23 Lineas de celulas de mamifero con desactivacion genica.

Country Status (13)

Country Link
US (1) US20220154207A1 (es)
EP (1) EP4217482A1 (es)
JP (1) JP2023542228A (es)
KR (1) KR20230068415A (es)
CN (1) CN116391037A (es)
AR (1) AR123609A1 (es)
AU (1) AU2021347580A1 (es)
BR (1) BR112023005426A2 (es)
CA (1) CA3195257A1 (es)
IL (1) IL301366A (es)
MX (1) MX2023003328A (es)
TW (1) TW202223092A (es)
WO (1) WO2022063877A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023202967A1 (en) 2022-04-19 2023-10-26 F. Hoffmann-La Roche Ag Improved production cells
WO2023232961A1 (en) * 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Improved production cells

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
EP0557459B1 (en) 1990-11-13 1997-10-22 Immunex Corporation Bifunctional selectable fusion genes
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
ES2528794T3 (es) 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7838503B2 (en) 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
AU2007229698B9 (en) 2006-03-24 2012-11-08 Merck Patent Gmbh Engineered heterodimeric protein domains
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
WO2010136172A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP2726510B1 (en) 2011-05-27 2023-03-08 F. Hoffmann-La Roche AG Dual targeting
SI2748202T1 (sl) 2011-08-23 2018-10-30 Roche Glycart Ag Bispecifične molekule, ki se vežejo na antigen
CA2859667C (en) 2011-12-20 2022-05-24 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
MX360109B (es) 2012-04-20 2018-10-23 Merus Nv Metodos y medios para la produccion de moleculas de tipo ig.
CN105849124B (zh) 2013-12-20 2022-04-12 豪夫迈·罗氏有限公司 双重特异性抗体
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
CN106573986A (zh) 2014-07-29 2017-04-19 豪夫迈·罗氏有限公司 多特异性抗体
CN107787332B (zh) 2015-04-24 2022-09-09 豪夫迈·罗氏有限公司 多特异性抗原结合蛋白
EP3308778A1 (en) 2016-10-12 2018-04-18 Institute for Research in Biomedicine Arginine and its use as a t cell modulator
US20210002669A1 (en) 2017-12-22 2021-01-07 Genentech, Inc. Targeted integration of nucleic acids

Also Published As

Publication number Publication date
TW202223092A (zh) 2022-06-16
US20220154207A1 (en) 2022-05-19
CA3195257A1 (en) 2022-03-31
IL301366A (en) 2023-05-01
WO2022063877A1 (en) 2022-03-31
AU2021347580A1 (en) 2023-04-06
CN116391037A (zh) 2023-07-04
JP2023542228A (ja) 2023-10-05
EP4217482A1 (en) 2023-08-02
KR20230068415A (ko) 2023-05-17
BR112023005426A2 (pt) 2023-05-09
AR123609A1 (es) 2022-12-21

Similar Documents

Publication Publication Date Title
MX2023003328A (es) Lineas de celulas de mamifero con desactivacion genica.
MX2021015823A (es) Lineas celulares de mamifero con inactivacion del gen sirtuina-1 (sirt-1).
MX2021000893A (es) Levadura que expresa enzimas para la producción de etanol.
RU2013152982A (ru) Способ снижения гетерогенности антител и способ получения соответствующих антител
MX2018002121A (es) Elaboracion de fosfatasas alcalinas.
WO2017051347A3 (en) Cells and method of cell culture
PH12020550487A1 (en) Method for improving fetal hemoglobin expression
EP4253407A3 (en) Methods of producing long acting ctp-modified growth hormone polypeptides
WO2018150269A8 (en) MULTI-SITE SITE-SPECIFIC INTEGRATION CELLS FOR DIFFICULT PROTEINS TO BE EXPRESSED
CN102649192B (zh) 一种超标装配间隙下的真空电子束对接焊方法
SG11201901093PA (en) Production method for insoluble recombinant protein aggregate
MX2016007207A (es) Metodos mejorados para la produccion de polipeptidos recombinantes.
MX2021000934A (es) Linfocitos t que contienen nef y métodos para producirlos.
MX2016014222A (es) Celulas novedosas de vertebrados y metodos para la expresion recombinante de un polipeptido de interes.
WO2018108546A3 (de) Verfahren zur herstellung einer bipolarplatte, bipolarplatte für eine brennstoffzelle und brennstoffzelle
MX2022001959A (es) Produccion de celulas t a partir de celulas madre pluripotenciales inducidas (ipscs) con inactivacion del gen de activacion de recombinacion (rag).
MX2022004311A (es) Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.
MX2021001890A (es) Metodos de produccion para vectores virales.
MX2021004470A (es) Vesículas extracelulares para terapias dirigidas contra células supresoras de origen mieloide.
MX2023001596A (es) Métodos para enriquecer células t diseñadas genéticamente.
WO2022016166A3 (en) Differentiation of trophectoderm lineage cells from pluripotent stem cells
MX2021003955A (es) Levadura que expresa enzimas para la produccion de etanol.
CL2023000576A1 (es) Estrategias de suministro con asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina.
MX2020013633A (es) Metodos para producir proteinas recombinantes.
FI20185896A1 (fi) Paranneltu anodimateriaali ja anodi uudelleen ladattavaa akkua varten, menetelmä niiden valmistamiseksi ja niistä tehty sähkökemiallinen kenno